



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: May 25, 2018

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Security Code: 540596	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 Symbol: ERIS
---	--

SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e. MAY 25, 2018

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. May 25, 2018 duly approved and took on record the Audited Standalone Financial Results and the Audited Consolidated Financial Results for the quarter and year ended March 31, 2018.

M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, Statutory Auditors of the Company has issued its Audit Report with unmodified opinion on the standalone and consolidated Financial Results of the Company for the year ended 31st March, 2018.

Please find enclosed herewith the duly signed Audited Standalone Financial Results and the Audited Consolidated Financial Results for the quarter and year ended March 31, 2018 along-with the Auditor's Report and Declaration for unmodified opinion.

The meeting of the Board of Directors commenced at 11:15 a.m. and concluded at 15:20 p.m.

This is for your information and record.

Thanking You

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Encl: a/a

Registered Office:

6th, 7th & 8th Floor, Commerce House - IV, Nr. Prahlad Nagar Garden, 100 Ft. Road, Ahmedabad - 380 015, Gujarat, India
Phone: +91 - 79 - 30451111 / 30179400 - 03 * Fax: +91 - 79 - 30179404 / 30451001 * Email: eris@erislifesciences.com * Web Site: www.eris.co.in
CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED March 31, 2018

Particulars	[Rs. in Million except per share data]					
	For Quarter Ended			For Year Ended		
	March 31, 2018 (Audited) (refer note-9)	December 31, 2017 (Unaudited)	March 31, 2017 (Unaudited) (refer note-8,9)	March 31, 2018 (Audited)	March 31, 2017 (Audited)	
Income						
Revenue from Operations	1,940.74	1,822.08	1,671.23	7,606.01	7,129.04	
Other Income	82.02	60.16	67.18	282.23	250.79	
Total Income	2,022.76	1,882.24	1,738.41	7,888.24	7,379.83	
Expenses						
Cost of materials consumed	125.24	114.41	70.46	470.79	453.75	
Purchase of stock-in-trade	167.25	320.59	93.22	648.90	532.35	
Changes in inventories of Finished goods, Work-in-Progress and Stock-in-trade	(6.24)	(171.46)	65.54	(35.43)	80.86	
Employee Benefits Expense	356.91	352.25	274.67	1,308.45	1,163.12	
Finance Costs	77.23	27.06	0.58	104.29	7.95	
Depreciation & Amortisation Expense	77.69	56.09	58.06	217.92	214.41	
Other Expenses	575.93	414.13	612.62	2,054.43	2,187.54	
Total Expenses	1,374.01	1,113.07	1,175.15	4,769.35	4,639.98	
Profit before Tax	648.75	769.17	563.26	3,118.89	2,739.85	
Tax Expense						
Current Tax	140.43	168.88	114.30	679.46	557.59	
Deferred Tax	(66.64)	(138.86)	(76.05)	(497.12)	(299.15)	
Total Tax Expense	73.79	30.02	38.25	182.34	258.44	
Net Profit for the period	574.96	739.15	525.01	2,936.55	2,481.41	
Other Comprehensive Income	2.95	(1.22)	(1.23)	(0.73)	(4.91)	
Items that will not be reclassified to profit or loss	4.51	(1.87)	(1.88)	(1.12)	(7.51)	
Income tax relating to items that will not be reclassified to profit or loss	(1.56)	0.65	0.65	0.39	2.60	
Total Comprehensive Income	577.91	737.93	523.78	2,935.82	2,476.50	
Paid Up Equity Share Capital (Face Value of Rs.1 each)	137.50	137.50	137.50	137.50	137.50	
Earnings Per Share (of Rs. 1 each) (not annualised) :						
Basic	4.18	5.38	3.82	21.36	18.05	
Diluted	4.18	5.38	3.82	21.36	18.05	
See accompanying notes to the financial results						



Jaehin Shah



Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

1. Statement of Standalone Audited Assets and Liabilities

(Rs. in Million)

Particulars	As at	As at
	March 31, 2018 (Audited)	March 31, 2017 (Audited)
I. ASSETS :		
(1) Non current assets		
(a) Property, plant and equipment	504.85	537.50
(b) Goodwill	166.60	-
(c) Intangible assets	4,226.02	380.26
(d) Financial assets		
Non current investments	4,518.37	2,904.29
Other financial asset	101.27	90.03
(e) Income tax assets (net)	68.24	68.23
(f) Deferred tax assets (net)	952.51	455.00
Total Non current assets	10,537.86	4,435.31
(2) Current assets		
(a) Inventories	575.20	472.01
(b) Financial assets		
Current investments	937.59	901.78
Trade receivables	604.96	413.02
Cash and cash equivalents	88.08	20.00
Other bank balances	0.06	0.55
Short-term loans	403.71	158.08
Other financial assets	75.27	98.70
(c) Other current assets	477.02	67.40
Total Current assets	3,161.89	2,131.54
TOTAL- ASSETS	13,699.75	6,566.85
II. EQUITY AND LIABILITIES :		
(1) Equity		
(a) Share capital	137.50	137.50
(b) Other Equity	8,544.29	5,608.47
Total Equity	8,681.79	5,745.97
(2) Non Current Liabilities		
(a) Financial Liabilities		
Long term Borrowings	2,736.88	-
Other financial liabilities	17.74	17.19
(b) Long-term provisions	150.16	185.35
(c) Other non-current liabilities	11.06	10.30
Total Non Current Liabilities	2,915.84	212.84
(3) Current liabilities		
(a) Financial Liabilities		
Trade payables	790.30	251.11
Other financial liabilities	1,030.26	71.52
(b) Short-term provisions	160.11	210.18
(c) Other current liabilities	95.88	52.38
(d) Income tax liabilities (net)	25.57	22.85
Total Current Liabilities	2,102.12	608.04
Total Liabilities	5,017.96	820.88
TOTAL- EQUITY AND LIABILITIES	13,699.75	6,566.85



Jaehin Shah



2. The above statement of financial results ("the Statement") of the Company were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 25, 2018.
- 3 (a) The Company has completed acquisition of Indian domestic formulation business of Strides Shasun Limited for ₹ 5000 millions and 100% shareholding of UTH Healthcare Limited for ₹ 128.50 millions. The Company is in the process of making a final determination of fair value for the purpose of Purchase price allocation and pending this the amortization of intangible assets in the books of accounts has been taken based on management estimates and draft fair valuation report.

(b) Consequent to that, during the year ended March 31, 2018 expense pertaining to Acquisition of Strides Shasun Limited includes :
 - (i) Legal professional expenses amounting to ₹ 35.89 millions shown in other expenses and
 - (ii) Resulting Deferred tax expense amount of ₹ 153.75 millions.
4. Revenue from operations for periods up to June 30, 2017 includes excise duty, which is discontinued effective July 1, 2017 upon implementation of Goods and Services Tax (GST) in India. In accordance with Ind AS-18, "Revenue", GST is not included in revenue from operations. On transition to GST, the Company has changed its incentive structure which would have consequential impact on sales return, the same has been adjusted during the period. In view of the aforesaid, revenue from operations for the quarter and year ended on March 31, 2018 are not comparable with the previous periods.
5. The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
6. The Company has introduced 'Eris Lifesciences Employee Stock Option Plan 2017' ("ESOP 2017"/ "Plan") through the resolution passed by the Board of Directors on 2nd February, 2017 and the same was approved by the shareholders at the extra ordinary general meeting held on 3rd February, 2017. Under the Scheme, 391,599 (Three lakhs ninety one thousand five hundred ninety nine only) equity shares have been granted to eligible employees of the Company and each option (after it is vested) is exercisable for one equity share having face value of ₹ 1 each for an exercise price of ₹ 451. Vesting of the options shall take place over a maximum period of 5 years with a minimum vesting period of 1 year from the date of grant i.e. 12th April, 2017. The exercise period would be a maximum of 5 years from the date of vesting of options.
7. The Company was listed on June 29, 2017 and the Statement has been drawn for the first time in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Obligations"). Since the results for the Year ended March 31, 2017 were not presented under the Indian GAAP ("Previous GAAP"), the reconciliation of Profit / Loss under Previous GAAP to Total Comprehensive Income under Ind AS is not presented.
8. The Company was listed on June 29, 2017. The financial results for the quarter ended 31st March, 2017 were not required to be published by the Company and the same were not reviewed by the statutory auditors. Hence, the financial results for the quarter ended 31st March, 2017 have been presented based on the information compiled by the management after making necessary adjustments to give true and fair view of the results in accordance with Ind AS.
9. The figures for the quarter ended March 31, 2018 and quarter ended March 31, 2017 as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the relevant financial year.
10. Figures for the previous periods have been regrouped/reclassified, wherever considered necessary.

For Eris Lifesciences Limited,

Amit Bakshi
Chairman and Managing Director
DIN : 01250925

Place: Ahmedabad
Date : May 25, 2018



**INDEPENDENT AUDITOR'S REPORT
TO THE BOARD OF DIRECTORS OF
ERIS LIFESCIENCES LIMITED
(Formerly Known as Eris Lifesciences Private Limited)**

1. We have audited the accompanying Statement of Standalone Financial Results of **ERIS LIFESCIENCES LIMITED (Formerly Known as Eris Lifesciences Private Limited)** ("the Company"), for the year ended 31st March, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related standalone Ind AS financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such standalone financial statements.

As stated in Note 8 of the Statement, we have not performed a review or audit of the figures relating to the corresponding Quarter ended 31st March, 2017.

3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us the Statement:
 - (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and



(ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and Total comprehensive income and other financial information of the Company for the year ended 31st March, 2018.

5. The Statement includes the results for the Quarter ended 31st March, 2018 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



A handwritten signature in blue ink, appearing to read "Gaurav J. Shah".

Gaurav J. Shah
Partner
(Membership No. 35701)

Place: Ahmedabad
Date: May 25 2018



STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2018

Particulars	For Quarter Ended			For Year Ended	
	March 31, 2018 (Audited) (refer note-9)	December 31, 2017 (Unaudited)	March 31, 2017 (Unaudited) (refer note-8,9)	March 31, 2018 (Audited)	March 31, 2017 (Audited)
Revenue from Operations	2,121.92	2,089.71	1,836.87	8,556.04	7,494.96
Other Income	73.05	57.84	52.50	264.08	251.13
Total Income	2,194.97	2,147.55	1,889.37	8,820.12	7,746.09
Expenses					
Cost of materials consumed	125.24	114.41	70.46	470.79	504.57
Purchase of stock-in-trade	217.76	425.08	211.87	898.36	572.74
Changes in inventories of Finished goods, Work-in-Progress and Stock-in-trade	(13.41)	(202.80)	0.43	(28.53)	(30.99)
Employee Benefits Expense	415.82	428.19	334.64	1,573.22	1,312.20
Finance Costs	77.55	27.63	1.89	105.50	10.33
Depreciation & Amortisation Expense	90.64	66.85	65.01	256.42	227.61
Other Expenses	659.23	513.93	728.98	2,422.07	2,445.76
Total Expenses	1,572.83	1,373.29	1,413.28	5,697.83	5,042.22
Profit before Tax	622.14	774.26	476.09	3,122.29	2,703.87
Tax Expense					
Current Tax	139.57	169.19	114.30	687.93	570.35
Deferred Tax	(78.21)	(144.14)	(103.46)	(515.42)	(332.55)
Total Tax Expense	61.36	25.05	10.84	172.51	237.80
Net Profit for the period	560.78	749.21	465.25	2,949.78	2,466.07
Attributable to :					
- Owners of the company	557.87	746.13	472.19	2,941.05	2,467.85
- Non controlling interest	2.91	3.08	(6.94)	8.73	(1.78)
Other Comprehensive Income	4.28	(1.20)	(1.23)	0.66	(4.91)
Items that will be reclassified to profit or loss	6.35	(1.85)	(1.88)	0.78	(7.51)
Income tax relating to items that will be reclassified to profit or loss	(2.07)	0.65	0.65	(0.12)	2.60
Total Comprehensive Income	565.06	748.01	464.02	2,950.44	2,461.16
Attributable to :					
- Owners of the company	562.15	744.93	470.96	2,941.71	2,462.94
- Non controlling interest	2.91	3.08	(6.94)	8.73	(1.78)
Paid Up Equity Share Capital (Face Value of Rs.1 each)	137.50	137.50	137.50	137.50	137.50
Earnings Per Share (of Rs. 1 each) (not annualised) :					
Basic	4.06	5.43	3.43	21.39	17.95
Diluted	4.06	5.43	3.43	21.39	17.95
See accompanying notes to the financial results					



Signature of Sachin Shah



Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

1. Statement of Consolidated Audited Assets and Liabilities

(Rs. in Million)

Particulars	As at	As at
	March 31, 2018 (Audited)	March 31, 2017 (Audited)
I. ASSETS :		
(1) Non current assets		
(a) Property, plant and equipment	526.12	556.77
(b) Capital Work in progress	-	0.74
(c) Goodwill	934.74	378.11
(d) Intangible assets	6,250.06	1,381.59
(e) Financial assets		
Non current investments	2,716.10	2,130.52
Other financial asset	101.91	90.72
(f) Income tax assets (net)	79.18	68.74
(g) Deferred tax assets (net)	1,005.67	498.93
Total Non current assets	11,613.78	5,106.12
(2) Current assets		
(a) Inventories	654.48	558.19
(b) Financial assets		
Current investments	937.59	901.78
Trade receivables	666.42	488.59
Cash and cash equivalents	106.08	23.43
Other bank balances	0.30	0.78
Loans	11.84	8.14
Other financial assets	83.04	103.50
(c) Other current assets	527.32	76.01
Total Current assets	2,987.07	2,160.42
TOTAL- ASSETS	14,600.85	7,266.54
II. EQUITY AND LIABILITIES :		
(1) Equity		
(a) Share capital	137.50	137.50
(b) Other Equity	8,475.57	5,533.86
Equity attributable to the owners of the company	8,613.07	5,671.36
Non-controlling Interest	246.65	237.93
Total Equity	8,859.72	5,909.29
(2) Non Current Liabilities		
(a) Financial Liabilities		
Long term Borrowings	2,741.95	4.94
Other financial liabilities	22.59	25.29
(b) Long-term provisions	187.13	211.52
(c) Other non-current liabilities	12.16	10.78
(d) Deferred tax liabilities (net)	522.70	346.54
Total Non Current Liabilities	3,486.53	599.07
(3) Current liabilities		
(a) Financial Liabilities		
Trade payables	907.74	385.17
Other financial liabilities	1,034.36	73.06
(b) Short-term provisions	170.71	215.01
(c) Other current liabilities	116.22	62.09
(d) Income tax liabilities (net)	25.57	22.85
Total Current Liabilities	2,254.60	758.18
Total Liabilities	5,741.13	1,357.25
TOTAL- EQUITY AND LIABILITIES	14,600.85	7,266.54



Jaishankar Shah



2. The above statement of financial results ("the Statement") of the Company were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 25, 2018.
- 3 (a) The Company has completed acquisition of Indian domestic formulation business of Strides Shasun Limited for ₹ 5000 millions and 100% shareholding of UTH Healthcare Limited for ₹ 128.50 millions. The Company is in the process of making a final determination of fair value for the purpose of Purchase price allocation and pending this the amortization of intangible assets in the books of accounts has been taken based on management estimates and draft fair valuation report.
- (b) Consequent to that, during the year ended March 31, 2018 expense pertaining to Acquisition of Strides Shasun Limited includes :
- Legal professional expenses amounting to ₹ 35.89 millions shown in other expenses and
 - Resulting Deferred tax expense amount of ₹153.75 millions.
4. Revenue from operations for periods up to June 30, 2017 includes excise duty, which is discontinued effective July 1, 2017 upon implementation of Goods and Services Tax (GST) in India. In accordance with Ind AS 18, "Revenue", GST is not included in revenue from operations. On transition to GST, the Company has changed its incentive structure which would have consequential impact on sales return, the same has been adjusted during the period. In view of the aforesaid, revenue from operations for the quarter and year ended on March 31, 2018 are not comparable with the previous periods.
5. The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
6. The Company has introduced 'Eris Lifesciences Employee Stock Option Plan 2017' ("ESOP 2017"/ "Plan") through the resolution passed by the Board of Directors on 2nd February, 2017 and the same was approved by the shareholders at the extra ordinary general meeting held on 3rd February, 2017. Under the scheme, 391,599 (Three lakhs ninety one thousand five hundred ninety nine only) equity shares have been granted to eligible employees of the company and each option (after it is vested) is exercisable for one equity share having face value of ₹ 1 each for an exercise price of ₹ 451. Vesting of the options shall take place over a maximum period of 5 years with a minimum vesting period of 1 year from the date of grant i.e. 12th April, 2017. The exercise period would be a maximum of 5 years from the date of vesting of options.
7. The Company was listed on June 29, 2017 and the Statement has been drawn for the first time in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Obligations"). Since the results for the Year ended March 31, 2017 were not presented under the Indian GAAP ("Previous GAAP"), the reconciliation of Profit / Loss under Previous GAAP to Total Comprehensive Income under Ind AS is not presented.
8. The Company was listed on June 29, 2017. The financial results for the quarter ended 31st March, 2017 were not required to be published by the Company and the same were not reviewed by the statutory auditors. Hence, the financial results for the quarter ended 31st March, 2017 have been presented based on the information compiled by the management after making necessary adjustments to give true and fair view of the results in accordance with Ind AS.
9. The figures for the quarter ended March 31, 2018 and quarter ended March 31, 2017 as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the relevant financial year.

10. Information of Standalone audited Financial Result of the Company is as Under:

(Rs. in Million)

Particulars	Quarter Ended			Year Ended	
	March 31, 2018 (Audited)	December 31, 2017 (Unaudited)	March 31, 2017 (Refer note-8)	2018 (Audited)	March 31, 2017 (Audited)
Revenue from Operations	1,940.74	1,822.08	1,671.23	7,606.01	7,129.04
Profit Before Tax	648.75	769.17	563.26	3,118.89	2,739.85
Net Profit for the period	574.96	739.15	525.01	2,936.55	2,481.41

11. Figures for the previous periods have been regrouped/reclassified, wherever considered necessary.

For Eris Lifesciences Limited,

Amit Bakshi
Chairman and Managing Director
DIN : 01250925

Place: Ahmedabad
Date : May 25, 2018



**INDEPENDENT AUDITORS' REPORT
TO THE BOARD OF DIRECTORS OF
ERIS LIFESCIENCES LIMITED
(Formerly Known as Eris Lifesciences Private Limited)**

1. We have audited the accompanying Statement of Consolidated Financial Results of **ERIS LIFESCIENCES LIMITED (Formerly Known as Eris Lifesciences Private Limited)** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the year ended 31/03/2018 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such consolidated financial statements.

As stated in Note 8 of the Statement, we have not performed a review or audit of the figures relating to the corresponding Quarter ended March 31, 2017.

3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Parent's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Parent's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph 5 below, is sufficient and appropriate to provide a basis for our audit opinion.



4. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements of the Group and subsidiaries referred to in paragraph 5 below, the Statement:
- a. includes the results of the following entities:
- (1) Eris Lifesciences Limited (Parent)
 - (2) Aprica Healthcare Private Limited (Subsidiary)
 - (3) Kinedex Healthcare Private Limited (Subsidiary)
 - (4) Eris Therapeutics Private Limited (Subsidiary)
 - (5) UTH Healthcare Limited (Subsidiary- From 1st October, 2017)
 - (6) Eris Healthcare Private Limited (Formerly known as Strides Healthcare Private Limited) (Subsidiary- From 1st December, 2017)
- b. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
- c. gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit, Total comprehensive income and other financial information of the Group for the year ended 31st March, 2018.
5. We did not audit the financial statements five subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of Rs. 895.21 million as at 31st March, 2018, total revenues of Rs. 983.34 million, total net profit after tax of Rs. 28.84 million and total comprehensive income of Rs. 30.23 million for the year ended on that date, as considered in the consolidated financial results. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors.
- Our opinion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.
6. The Statement includes the results for the Quarter ended 31st March, 2018 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.



7. The comparative financial information for the quarter and year ended March 31, 2017 in respect of three and four subsidiaries respectively, prepared in accordance with the Ind AS and included in this Statement have been audited by other auditors whose reports have been furnished to us by the Management and in so far as it relates to the comparative amounts and disclosures included in respect of these subsidiaries made in this Statement, is based solely on the reports of the other auditors.

Our report is not qualified in respect of these matters.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



A handwritten signature in blue ink, appearing to read "Gaurav J. Shah".

Gaurav J. Shah
Partner
(Membership No. 35701)

Place: Ahmedabad
Date: May 25, 2018



Date: May 25, 2018

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Security Code: 540596	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 Symbol: ERIS
---	--

Dear Sir(s)

Subject: Declaration in respect of unmodified opinion on Audited Financial Statements for year ended 31st March 2018



Ref: Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We hereby declare that in the Audited Financial Results (standalone & consolidated) for the Financial Year ended 31st March 2018 which have been approved by the Board of Directors of the Company at their meeting held today i.e. 25th May 2018.

Our statutory Auditors M/s. Deloitte Haskins & Sells LLP, Chartered Accountants have issued Audit Report with unmodified opinion on the said financial results.

This is for your information and record.

For Eris Lifesciences Limited



Sachin Shah
Chief Financial Officer

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867